Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐versus‐host disease — a real‐world outcomes analysis

Summary Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identifi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-11, Vol.195 (3), p.429-432
Main Authors: Abedin, Sameem, Rashid, Nahid, Schroeder, Mark, Romee, Rizwan, Nauffal, Mary, Alhaj Moustafa, Muhamad, Kharfan‐Dabaja, Mohamed A., Palmer, Jeanne, Hogan, William, Hefazi, Mehrdad, Larson, Samantha, Holtan, Shernan, DeFilipp, Zachariah, Jayani, Reena, Dholaria, Bhagirathbhai, Pidala, Joseph, Khimani, Farhad, Grunwald, Michael R., Butler, Candace, Hamadani, Mehdi
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Aged
Allografts
Bone Marrow Transplantation - adverse effects
Cord Blood Stem Cell Transplantation - adverse effects
Drug Resistance
Female
Graft vs Host Disease - drug therapy
Graft vs Host Disease - mortality
Graft vs Host Disease - prevention & control
graft‐versus‐host disease
Hematology
Humans
Immunosuppressive Agents - therapeutic use
Intolerance
Male
Middle Aged
Nitriles - adverse effects
Nitriles - pharmacology
Nitriles - therapeutic use
Patients
Peripheral Blood Stem Cell Transplantation - adverse effects
Pyrazoles - adverse effects
Pyrazoles - pharmacology
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Retrospective Studies
Salvage Therapy
stem cell transplantation
Steroids
Survival
transplant
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR‐aGVHD studies.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17700